AVITA Medical (RCEL) Short term Debt (2025)

AVITA Medical (RCEL) posted Short term Debt of $43.0 million for Q4 2025, up 1332.8% on a QoQ basis from $3.0 million in Q3 2025.

AVITA Medical (RCEL) Short term Debt (2025) Analysis & Trends

AVITA Medical's Short term Debt history runs 1 years deep, the most recent figure standing at $43.0 million for Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $43.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $43.0 million (changed N/A YoY) and the FY2025 annual result came in at $43.0 million, changed N/A from the prior year.
Short term Debt was $43.0 million for Q4 2025 at AVITA Medical, up from $3.0 million in the prior quarter.
Across five years, Short term Debt topped out at $43.0 million in Q4 2025 and bottomed at $3.0 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	AVITA Medical	140.94 Mn	124.59 Mn	14.31 Mn

Download Data